OHRP


OHR Pharmaceutical Inc (OHRP) Loses Bull After Disappointing MAKO Trial Results

Roth Capital’s Yasmeen Rahimi is left bewildered, having banked on the success of OHRP’s wet-AMD asset, but holds out hope to become more positive on the stock down the line.

Here’s Why OHR Pharmaceutical Inc (OHRP) Shares Are Collapsing 80% Today

Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only …

Here’s Why OHR Pharmaceutical Inc (OHRP) Shares Jumped Today

An article was published on Seeking Alpha detailing a long position.

H.C. Wainwright Chimes in on OHR Pharmaceutical Inc (OHRP) and the Implications of Fovista’s Failings

OHR Pharmaceutical Inc (NASDAQ:OHRP) is confronting the aftermath of Fovista’s pivotal two Phase 3 failures that both missed the primary endpoint in neovascular …

Company Update (NASDAQ:OHRP): OHR Pharmaceutical Inc Announces Pricing of $7.75 Million Public Offering of Common Stock and Warrants

Ohr Pharmaceutical, Inc. (NASDAQ:OHRP) announced that it has priced a registered public offering of an aggregate of 3,875,000 shares of common stock at …

Stock Update (NASDAQ:OHRP): Here’s Why OHR Pharmaceutical Inc Shares Are Falling 18% Today

OHR Pharmaceutical Inc (NASDAQ:OHRP) announced this afternoon that it intends to offer and sell, subject to market and other conditions, shares of its common …

Company Update (NASDAQ:OHRP): OHR Pharmaceutical Inc Reports Second Quarter 2016 Financial and Business Results

OHR Pharmaceutical Inc (NASDAQ:OHRP), an ophthalmology research and development company, today reported results for its second quarter ended March 31, 2016. “We achieved a …

Company Update (NASDAQ:OHRP): OHR Pharmaceutical Inc Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee

OHR Pharmaceutical Inc (NASDAQ:OHRP), an ophthalmology research and development company, announced that David M. Brown, MD, Clinical Professor of Ophthalmology at Baylor College …

Company Update (NASDAQ:OHRP): OHR Pharmaceutical Inc Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program

OHR Pharmaceutical Inc (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, announced that the first patient has been enrolled in the …

Analysts Chime In on Three Volatile Biotech Stocks: TrovaGene Inc (TROV), Keryx Biopharmaceuticals (KERX), OHR Pharmaceutical Inc (OHRP)

Healthcare analysts are weighing in on molecular diagnostics firm TrovaGene Inc (NASDAQ:TROV), pharmaceutical company Keryx Biopharmaceuticals (NASDAQ:KERX), and mological drug maker OHR Pharmaceutical Inc (NASDAQ:OHRP), as the …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts